German SPRIND Launches ‘Orbital Bioworks’ Challenge, Offering Up to €1.65M for Microgravity Drug Development

July 5, 2026

SPRIND (German Federal Agency for Disruptive Innovation) Germany

Overview

Germany’s Federal Agency for Disruptive Innovation (SPRIND) has launched the ‘Orbital Bioworks’ challenge to unlock the potential of microgravity for drug development and biomanufacturing. The initiative targets three key areas: cell-free peptide manufacturing, stem cell differentiation, and organ-on-a-chip drug testing, providing up to 1.65 million euros per team. SPRIND aims to secure technological and industrial sovereignty for in-orbit production in Europe, potentially leading to breakthroughs in the pharmaceutical industry and diversifying the space economy.

In Depth

Key Findings

The German Federal Agency for Disruptive Innovation (SPRIND) has initiated the ‘Orbital Bioworks’ challenge, a bold program designed to catalyze research and development in drug discovery and biomanufacturing within the microgravity environment. This ambitious undertaking focuses on three critical areas: cell-free peptide manufacturing, controlled stem cell differentiation, and organ-on-a-chip drug testing, with selected teams eligible for significant funding of up to 1.65 million euros each. SPRIND’s overarching goal is to establish Europe’s technological and industrial leadership in orbital bioproduction, fostering a new era of space-enabled healthcare solutions.

Technical Details

Microgravity offers unique advantages that can enable processes difficult or impossible to achieve under Earth’s gravity. The ‘Orbital Bioworks’ challenge targets these specific areas:

Cell-Free Peptide Manufacturing: This involves synthesizing therapeutic peptides with higher purity and efficiency in microgravity, without relying on living cells. By minimizing gravitational sedimentation and convection, this method could reduce impurities and improve the yield of high-quality pharmaceutical ingredients compared to terrestrial processes.
Controlled Stem Cell Differentiation: Stem cells hold immense promise for medical applications, but precise and uniform differentiation into specific cell types remains a challenge. Microgravity is known to influence cell proliferation and differentiation pathways, potentially facilitating the formation of more homogeneous cell populations and complex tissue structures in three-dimensional cultures that are unattainable on Earth.
Organ-on-a-Chip Drug Testing: Organ-on-a-chip devices, which mimic human organ functions, are valuable tools for drug screening and an alternative to animal testing. In microgravity, these chips could provide more physiologically relevant models, enabling more accurate assessments of drug toxicity and efficacy. This could significantly streamline drug discovery and improve success rates in clinical trials.

These technologies have the potential to deliver breakthroughs in pharmaceutical research, advance regenerative medicine, and ultimately expand treatment options for patients.

Background & Context

The commercial viability of in-space biomanufacturing has seen rapid growth, evidenced by initiatives like LambdaVision’s artificial retina production. SPRIND’s ‘Orbital Bioworks’ challenge signals Europe’s intent to become a frontrunner in this critical emerging field. While Europe possesses a strong foundation in biotechnology research, its commercial space activities have lagged behind other regions. This challenge is a strategic endeavor to bridge that gap, propelling Europe’s scientific and industrial communities to the forefront of space biomanufacturing. The potential for cost reduction, increased efficiency in drug development, and the creation of novel pharmaceuticals could impact a multi-billion Euro market.

Strategic Significance & Outlook

The technologies developed through the ‘Orbital Bioworks’ challenge are expected to not only revolutionize pharmaceutical manufacturing processes but also contribute to the advancement of life-support systems for future space habitats. SPRIND’s substantial funding of up to 1.65 million euros provides a critical incentive for research teams to pursue high-risk, high-reward projects in their early stages. Success in this challenge could position Europe as a global leader in space biotechnology, contributing to solutions for terrestrial medical challenges while building a new pillar of the space economy. This will further diversify commercial activities in space and strengthen Europe’s technological autonomy and competitive standing on a global scale.

Source: https://www.sprind.org/en/actions/challenges/orbital-bioworks

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.